The success rate and associated risk factors of CT-guided percutaneous radiofrequency sympathectomy in the treatment of primary hyperhidrosis: A retrospective observational trial

医学 多汗症 置信区间 优势比 经皮 逻辑回归 交感神经切除术 外科 回顾性队列研究 观察研究 病历 内科学
作者
Zixin Han,Rui Min,Chaobo Ni,Jianjun Zhu,Longsheng Xu,Ming Yao
出处
期刊:Journal of Clinical Neuroscience [Elsevier]
卷期号:118: 81-89 被引量:1
标识
DOI:10.1016/j.jocn.2023.10.010
摘要

The aim of this study was to investigate the success rate of surgical technique and associated risk factors based on the follow-up of patients who underwent CT-guided percutaneous radiofrequency sympathectomy (RFS) to treat primary hyperhidrosis (PH).370 patients who underwent RFS for PH treatment between January 2018 and April 2022 were enrolled. Patients responded to a questionnaire and telephone follow-up on the effects of treatment and their electronic medical records and imaging findings were reviewed. Logistic regression was performed to identify risk factors related to the success rate of surgical technique.A temperature difference ≥2 °C before and after procedure was defined as a successful surgical technique. Among the 370 patients (740 sides), 637 sides had successful RFS, and the technical success rate was 86.1 %. Immediately after procedure, 636 sides (85.9 %) were completely dry, 64 (8.7 %) were partially dry, and 40 (5.4 %) were still wet. During the longest follow-up period (54 months), 103 patients relapsed. The median hyperhidrosis disease severity scale score on both sides decreased from 4 to 1 after RFS. According to logistic regression analysis, only the pre-post pulse index was associated with the success rate of surgical technique (odds ratio, 1.14; 95 % confidence interval, 1.06-1.23; p = 0.0004).We observed that the immediate efficiency and success rate of surgical technique after RFS for PH treatment were relatively high, although there is a possibility of recurrence in the long term. In general, RFS is a safe and effective procedure for alleviating the symptoms of patients with hyperhidrosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lt_zyk完成签到,获得积分10
1秒前
1秒前
wary发布了新的文献求助10
2秒前
清爽老九完成签到,获得积分10
2秒前
Orange应助张鱼小丸子采纳,获得10
2秒前
3秒前
4秒前
雨夜星空完成签到,获得积分10
4秒前
饱满的半青完成签到 ,获得积分10
5秒前
5秒前
务实盼海发布了新的文献求助10
5秒前
Jouleken完成签到,获得积分10
5秒前
6秒前
zq00完成签到,获得积分10
6秒前
6秒前
斯文败类应助独木舟采纳,获得10
6秒前
易哒哒完成签到,获得积分10
6秒前
CCL应助QXS采纳,获得50
7秒前
大方安白完成签到,获得积分10
7秒前
Xxaaa完成签到,获得积分20
7秒前
张小敏完成签到,获得积分10
8秒前
9秒前
9秒前
9秒前
科研通AI2S应助Zhong采纳,获得10
9秒前
yidashi完成签到,获得积分10
9秒前
Kelvin.Tsi完成签到 ,获得积分10
9秒前
Island发布了新的文献求助10
10秒前
hu970发布了新的文献求助10
10秒前
九九发布了新的文献求助10
10秒前
123456完成签到,获得积分10
10秒前
BareBear应助龙妍琳采纳,获得10
10秒前
赘婿应助wary采纳,获得10
11秒前
小蘑菇应助wary采纳,获得10
11秒前
上官若男应助wary采纳,获得10
11秒前
李爱国应助木子采纳,获得10
11秒前
烟花应助马佳凯采纳,获得10
11秒前
11秒前
LYL完成签到,获得积分10
12秒前
12秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762